Abstract

The histologic distinction of small cell from non-small cell lung carcinoma and correct identification of all subtypes of lung carcinoma are very important in treatment management. The main method for histologic classification of lung tumors is based on morphology. However, in small bronchoscopic biopsies in particular, distinction is very difficult upon morphology alone. The current study aimed at evaluating the utility of a panel of antibodies, consisting of thyroid transcription factor (TTF-1), P63, high molecular weight keratin [HMWK (34βE12)], cytokeratin (CK7), and cluster of differentiation (CD56) for accurate distinction of bronchogenic carcinomas. Bronchoscopic biopsies of 60 lung carcinoma cases including 20 small cell carcinomas, 20 adenocarcinomas, and 20 squamous cell carcinomas (SCCs) with typical morphologic features were selected. All these cases were immunohistochemically stained for TTF-1, P63, HMWK (34βE12), CK7, and CD56. All immunostained slides were scored as either positive or negative. The mean age of the patients was 60 years; ranged from 35 to 81. Sixteen patients were female and 44 were male. All adenocarcinomas were positive for CK7 and most of them (18/20; 90%) were positive for TTF-1. Most of small cell lung carcinomas were positive for TTF-1 (17/20; 85%), and CD56 (18/20; 90%). All squamous cell carcinomas (SCCs) were negative for TTF-1, but most of them were positive for HMWK (34βE12) and P63. The obtained data showed that TTF-1, P63, CK7, CD56 and/or 34βE12 represent a useful panel of antibodies to identify lung carcinoma subtypes in small bronchoscopicbiopsies.

Highlights

  • Worldwide, 1.8 million patients were diagnosed with lung cancer in 2012 that caused an estimated 1.6 million deaths [1]

  • The current study aimed at evaluating the utility of a panel of antibodies, consisting of thyroid transcription factor (TTF-1), P63, high molecular weight keratin [HMWK (34βE12)], cytokeratin (CK7), and cluster of differentiation (CD56) for accurate distinction of bronchogenic carcinomas

  • Most of small cell lung carcinomas were positive for TTF-1 (17/20; 85%), and CD56 (18/20; Published Online 01 Jul 2017; 90%)

Read more

Summary

Introduction

1.8 million patients were diagnosed with lung cancer in 2012 that caused an estimated 1.6 million deaths [1]. Due to decreased smoking habits, there is a decline in lung cancer deaths in both genders [3]. The 2015 World Health Organization (WHO) classification that should be the foundation for lung cancer recognizes four major histologic cell types[4]: Adenocarcinoma (including bronchioalveolar carcinoma), squamous cell carcinoma, large cell carcinoma, and small cell carcinoma. Compared to previous classification systems, to a greater extent it relies on immunohistochemistry to subtype lung cancers and provides standardized criteria and terminology to diagnose small biopsies and cytology, which are the main sampling methods in patients with highstage cancers. The main method for histologic classification of lung tumors is based on morphology. The current study aimed at evaluating the utility of a panel of antibodies, consisting of thyroid transcription factor (TTF-1), P63, high molecular weight keratin [HMWK (34βE12)], cytokeratin (CK7), and cluster of differentiation (CD56) for accurate distinction of bronchogenic carcinomas

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call